BIOMARIN PHARMACEUTICAL INC 8-K

What Happened

• BioMarin Pharmaceutical Inc. filed an 8-K (Item 8.01) reporting that on April 23, 2026 the Ministry of Economics and Finance in France granted foreign direct investment clearance for BioMarin’s previously announced merger with Amicus Therapeutics, Inc. The Merger Agreement (entered December 19, 2025) provides for Lynx Merger Sub 1, Inc. (a BioMarin subsidiary) to merge into Amicus, with Amicus surviving as a wholly owned subsidiary of BioMarin. With the French FDI clearance received, the filing states the remaining closing conditions are those to be satisfied at closing, and the Merger is expected to close on April 27, 2026.

Key Details

• Merger Agreement signed: December 19, 2025 (Lynx Merger Sub 1, Inc. is the acquiring subsidiary).
• French FDI Clearance granted: April 23, 2026 by the Ministry of Economics and Finance in France.
• Expected closing date: April 27, 2026 (clearance satisfies final condition other than any conditions to be met at closing).
• Post-close structure: Amicus will become a wholly owned subsidiary of BioMarin.

Why It Matters

• The French clearance removes a key regulatory hurdle and brings the transaction to the verge of closing, which is material for both companies’ shareholders.
• A closing on the expected date would complete BioMarin’s acquisition of Amicus under the agreed terms and change Amicus shareholders’ ownership status (to being owned by BioMarin).
• The filing includes customary forward‑looking statements and risk disclosures; actual results could differ and both companies say they are not obligated to update these statements. Investors should review the companies’ SEC filings (including their 2025 Form 10‑K risk factors and Amicus’s proxy statement) for potential risks related to consummating the Merger.